|
Comprehensive Care for Patients With ADHD: A Practical, Interactive Initiative
CME/CE-Certified Newsletter 1 Released April 2008; New format June 2008
Focus on Complex Patients
WELCOME Complex patients are, by definition, particularly challenging to the clinician. In treating ADHD, there are numerous questions about appropriate selection of therapeutic agents and management of patients who either do not respond to treatment or have comorbidities that complicate therapeutic decision-making. Recently, I was pleased to moderate a wide-ranging discussion with my colleagues, Larry Culpepper, MD, MPH, and Margaret D. Weiss, MD, PhD, who offered their clinical guidance on many of these difficult issues. This newsletter summarizes the roundtable content.
Sincerely,
Timothy E. Wilens, MD, Editor Associate Professor, Psychiatry Harvard Medical School Director of Substance Abuse Services, Clinical and Research Programs Pediatric Psychopharmacology Research Program Massachusetts General Hospital Boston, Massachusetts
Method of Participation Read this newsletter, complete the CME/CE Activity Evaluation and Request for Credit Form online, and receive your statement of credit immediately. Print your statement of credit. This activity is provided free of charge to participants.
Intended Audience Psychiatrists, primary care physicians, and nurse practitioners
Release/Expiration Dates April 2008 through June 30, 2009
Estimated Time to Complete 1 hour
Accreditation/Designation of Credit Statements Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Family Physicians This activity has been reviewed and is acceptable for up to 1 Prescribed credit(s) by the American Academy of Family Physicians. AAFP accreditation begins April 2008. Term of approval is for one year from this date with option for yearly renewal.
Nurse Practitioners Veritas Institute for Medical Education, Inc. approved as a provider for nurse practitioner continuing education by the American Academy of Nurse Practitioners: AANP Provider Number 040309. This program has been approved for 1 contact hour of continuing education (which includes 1 hour of pharmacology).
Sponsorship and Support
Financial Disclosure Statements In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Disclosures are as follows:
Timothy E. Wilens, MD―Abbott Laboratories, Cephalon Inc, Eli Lilly and Company, Merck and Co., Inc., National Institute of Mental Health, National Institute on Drug Abuse, Novartis Pharmaceuticals Corporation, Ortho-McNeil Janssen Scientific Affairs, LLC, Shire (grant/research support, speakers bureau, and/or consultant).
Larry Culpepper, MD, MPH—AstraZeneca, Forest Laboratories, Eli Lilly and Company, Neurocrine, Pfizer Inc, Wyeth (speakers bureau and/or consultant), Blue Cross Foundation of Massachusetts (grant/research support).
Margaret D. Weiss, MD, PhD—Eli Lilly and Company, Ortho-McNeil Janssen Scientific Affairs, LLC, Purdue, Shire, Takeda Pharmaceutical Company Limited (grant/research support, speakers bureau, and/or consultant).
The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.
Unlabeled Use Disclosure Statement Participants are advised that this CME/CE activity will contain references to unlabeled/ unapproved/investigational uses of drugs to treat attention-deficit/hyperactivity disorder.
Disclaimer The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Veritas Institute for Medical Education, Inc. or McNeil Pediatrics administered by Ortho-McNeil Janssen Scientific Affairs, LLC. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.
Copyright © 2008 Veritas Institute for Medical Education, Inc. All rights reserved.
Editorial Board
Timothy E. Wilens, MD, Editor Associate Professor, Psychiatry Harvard Medical School Director of Substance Abuse Services, Clinical and Research Programs Pediatric Psychopharmacology Research Program Massachusetts General Hospital Boston, Massachusetts
Larry Culpepper, MD, MPH Professor and Chair, Family Medicine Boston University School of Medicine Chief, Family Medicine Boston Medical Center Boston, Massachusetts
Margaret D. Weiss, MD, PhD Clinical Full Professor, Director of Research, Psychiatry University of British Columbia Director of the Provincial ADHD Program, Psychiatry Children’s and Women’s Health Centre Vancouver, British Columbia, Canada
LEARNING OBJECTIVE You will be better able to treat patients with ADHD who are resistant to treatment with stimulants and/or have psychiatric or medical comorbidities.
|
